Plain-English translation of NCT02392572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new oral medication called ONC201 for patients with acute leukemia or myelodysplastic syndrome (a blood disorder) that has either come back after treatment or did not respond to standard treatments in the first place. The study will test different doses and schedules of the medication, and some patients may also receive it combined with another drug called . Researchers want to find the best dose, understand side effects, and measure how well this treatment works.
For patients whose blood cancers return or don't respond to standard chemotherapy, there are limited options and outcomes are often poor. This trial exists to see if this new medication might offer hope to patients who have run out of other treatment choices.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of five treatment groups, each taking the medication on a different schedule (ranging from once every 3 weeks to daily, or combined with another drug). Each treatment cycle lasts 21 or 28 days depending on your group. You will continue taking the medication as long as your cancer does not progress and you do not experience unacceptable side effects. Throughout the study, you'll have regular blood tests and clinic visits to monitor how the medication is working and check for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States